test

Alfred Ian Lee MD, PhD

Assistant Professor of Medicine (Hematology); Firm Chief, Inpatient Hematology, Yale Cancer Center; Assistant Program Director, Traditional Internal Medicine Residency Program

Clinical Interests

Bleeding, clotting, and platelet disorders; antiphospholipid antibody syndrome; eosinophilia; anemia; porphyria; histiocytic disorders; autoimmune hemolytic anemia; cryoglobulinemia


Board Certifications

2013
Hematology (Internal Medicine), Board Certified
2007
Internal Medicine, Board Certified

Patient Care Locations

alfred_leefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Hepatic Veno-Occlusive Disease, Hodgkin's Lymphoma, Leukemia, not otherwise specified, Multiple Myeloma, and Non-Hodgkin's LymphomaDefibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Antiphospholipid Syndrome (APS)Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Non-Hodgkin's LymphomaA randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30- positive mature T-cell lymphomas
HemophiliaAn ascending single dose study to evaluate the safety, tolerability and pharmacokinetics/pharmacodynamics of PF-05280602, a recombinant factor VIIa variant (813D), in adult hemophilia A and B subjects with or without inhibitors.

More Clinical Trials...

Edit Profile